questionsmedicales.fr
Lipides
Lipides membranaires
Sphingolipides
Glycosphingolipides
Glycosphingolipides acides
Gangliosides
Gangliosides : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Gangliosides : Questions médicales les plus fréquentes",
"headline": "Gangliosides : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Gangliosides : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-06",
"dateModified": "2025-03-31",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Gangliosides"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Glycosphingolipides acides",
"url": "https://questionsmedicales.fr/mesh/D020384",
"about": {
"@type": "MedicalCondition",
"name": "Glycosphingolipides acides",
"code": {
"@type": "MedicalCode",
"code": "D020384",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D10.570.877.360.025"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Ganglioside GM1",
"alternateName": "G(M1) Ganglioside",
"url": "https://questionsmedicales.fr/mesh/D005677",
"about": {
"@type": "MedicalCondition",
"name": "Ganglioside GM1",
"code": {
"@type": "MedicalCode",
"code": "D005677",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D10.570.877.360.025.475.390"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Ganglioside GM2",
"alternateName": "G(M2) Ganglioside",
"url": "https://questionsmedicales.fr/mesh/D005678",
"about": {
"@type": "MedicalCondition",
"name": "Ganglioside GM2",
"code": {
"@type": "MedicalCode",
"code": "D005678",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D10.570.877.360.025.475.400"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Ganglioside GM3",
"alternateName": "G(M3) Ganglioside",
"url": "https://questionsmedicales.fr/mesh/D005679",
"about": {
"@type": "MedicalCondition",
"name": "Ganglioside GM3",
"code": {
"@type": "MedicalCode",
"code": "D005679",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D10.570.877.360.025.475.510"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Gangliosides",
"alternateName": "Gangliosides",
"code": {
"@type": "MedicalCode",
"code": "D005732",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Sandro Sonnino",
"url": "https://questionsmedicales.fr/author/Sandro%20Sonnino",
"affiliation": {
"@type": "Organization",
"name": "Department of Medical Biotechnology and Translational Medicine, University of Milano, Segrate, Italy. sandro.sonnino@unimi.it."
}
},
{
"@type": "Person",
"name": "Laura Mauri",
"url": "https://questionsmedicales.fr/author/Laura%20Mauri",
"affiliation": {
"@type": "Organization",
"name": "Department of Medical Biotechnology and Translational Medicine, University of Milano, Segrate, Italy."
}
},
{
"@type": "Person",
"name": "Jin-Ichi Inokuchi",
"url": "https://questionsmedicales.fr/author/Jin-Ichi%20Inokuchi",
"affiliation": {
"@type": "Organization",
"name": "Division of Glycopathology, Institute of Molecular Biomembrane and Glycobiology, Tohoku Medical and Pharmaceutical University, Sendai, Japan."
}
},
{
"@type": "Person",
"name": "Ronald L Schnaar",
"url": "https://questionsmedicales.fr/author/Ronald%20L%20Schnaar",
"affiliation": {
"@type": "Organization",
"name": "Departments of Pharmacology and Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, United States."
}
},
{
"@type": "Person",
"name": "Massimo Aureli",
"url": "https://questionsmedicales.fr/author/Massimo%20Aureli",
"affiliation": {
"@type": "Organization",
"name": "Department of Medical Biotechnology and Translational Medicine, University of Milano, Segrate, Italy."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Progressive Paracentral Visual Field Loss at Low Intraocular Pressures Following LASIK.",
"datePublished": "2024-06-14",
"url": "https://questionsmedicales.fr/article/39141409",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/IJG.0000000000002395"
}
},
{
"@type": "ScholarlyArticle",
"name": "Human perception of spatial frequency varies with stimulus orientation and location in the visual field.",
"datePublished": "2023-10-17",
"url": "https://questionsmedicales.fr/article/37848541",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-023-44673-8"
}
},
{
"@type": "ScholarlyArticle",
"name": "Cortical magnification eliminates differences in contrast sensitivity across but not around the visual field.",
"datePublished": "2023-03-24",
"url": "https://questionsmedicales.fr/article/36961485",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.7554/eLife.84205"
}
},
{
"@type": "ScholarlyArticle",
"name": "Smoking Cessation May Reduce Risk of Visual Field Progression in Heavy Smokers.",
"datePublished": "2022-08-02",
"url": "https://questionsmedicales.fr/article/35939832",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/IJG.0000000000002092"
}
},
{
"@type": "ScholarlyArticle",
"name": "Insights into the relationship between eye movements and personality traits in restricted visual fields.",
"datePublished": "2024-05-04",
"url": "https://questionsmedicales.fr/article/38704441",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-024-60992-w"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Lipides",
"item": "https://questionsmedicales.fr/mesh/D008055"
},
{
"@type": "ListItem",
"position": 3,
"name": "Lipides membranaires",
"item": "https://questionsmedicales.fr/mesh/D008563"
},
{
"@type": "ListItem",
"position": 4,
"name": "Sphingolipides",
"item": "https://questionsmedicales.fr/mesh/D013107"
},
{
"@type": "ListItem",
"position": 5,
"name": "Glycosphingolipides",
"item": "https://questionsmedicales.fr/mesh/D006028"
},
{
"@type": "ListItem",
"position": 6,
"name": "Glycosphingolipides acides",
"item": "https://questionsmedicales.fr/mesh/D020384"
},
{
"@type": "ListItem",
"position": 7,
"name": "Gangliosides",
"item": "https://questionsmedicales.fr/mesh/D005732"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Gangliosides - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Gangliosides",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-15",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Gangliosides",
"description": "Comment diagnostiquer une maladie liée aux gangliosides ?\nQuels tests sont utilisés pour détecter les gangliosides ?\nLes symptômes peuvent-ils indiquer un problème de gangliosides ?\nQuelle imagerie est utile pour évaluer les gangliosides ?\nLes antécédents familiaux sont-ils importants pour le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D005732?mesh_terms=Visual+Fields&page=5#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Gangliosides",
"description": "Quels sont les symptômes courants des gangliosidoses ?\nLes gangliosides affectent-ils le système nerveux ?\nPeut-on observer des symptômes cutanés ?\nLes troubles cognitifs sont-ils liés aux gangliosides ?\nLes douleurs musculaires sont-elles un symptôme ?",
"url": "https://questionsmedicales.fr/mesh/D005732?mesh_terms=Visual+Fields&page=5#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Gangliosides",
"description": "Peut-on prévenir les gangliosidoses ?\nLe conseil génétique est-il recommandé ?\nLes vaccinations peuvent-elles aider ?\nL'alimentation peut-elle jouer un rôle préventif ?\nLes tests de dépistage sont-ils utiles ?",
"url": "https://questionsmedicales.fr/mesh/D005732?mesh_terms=Visual+Fields&page=5#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Gangliosides",
"description": "Quels traitements existent pour les gangliosidoses ?\nLa thérapie génique est-elle une option ?\nLes médicaments peuvent-ils aider ?\nY a-t-il des traitements expérimentaux disponibles ?\nLe soutien nutritionnel est-il important ?",
"url": "https://questionsmedicales.fr/mesh/D005732?mesh_terms=Visual+Fields&page=5#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Gangliosides",
"description": "Quelles complications peuvent survenir ?\nLes gangliosidoses peuvent-elles entraîner des handicaps ?\nY a-t-il un risque accru de maladies associées ?\nLes complications sont-elles réversibles ?\nComment gérer les complications ?",
"url": "https://questionsmedicales.fr/mesh/D005732?mesh_terms=Visual+Fields&page=5#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Gangliosides",
"description": "Quels sont les facteurs de risque des gangliosidoses ?\nLes origines ethniques influencent-elles le risque ?\nLes facteurs environnementaux jouent-ils un rôle ?\nLes antécédents médicaux familiaux sont-ils significatifs ?\nLes mutations génétiques sont-elles héréditaires ?",
"url": "https://questionsmedicales.fr/mesh/D005732?mesh_terms=Visual+Fields&page=5#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une maladie liée aux gangliosides ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des tests génétiques, des analyses biochimiques et des biopsies."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour détecter les gangliosides ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins et des analyses de tissus peuvent être effectués pour détecter les gangliosides."
}
},
{
"@type": "Question",
"name": "Les symptômes peuvent-ils indiquer un problème de gangliosides ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des symptômes neurologiques ou musculaires peuvent suggérer une dysfonction des gangliosides."
}
},
{
"@type": "Question",
"name": "Quelle imagerie est utile pour évaluer les gangliosides ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'IRM peut aider à visualiser les anomalies cérébrales associées aux gangliosidoses."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux sont-ils importants pour le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les antécédents familiaux de maladies génétiques peuvent orienter le diagnostic."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants des gangliosidoses ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des troubles neurologiques, des retards de développement et des problèmes moteurs."
}
},
{
"@type": "Question",
"name": "Les gangliosides affectent-ils le système nerveux ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les gangliosides sont essentiels pour le fonctionnement normal du système nerveux."
}
},
{
"@type": "Question",
"name": "Peut-on observer des symptômes cutanés ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines gangliosidoses peuvent provoquer des lésions cutanées ou des anomalies pigmentaires."
}
},
{
"@type": "Question",
"name": "Les troubles cognitifs sont-ils liés aux gangliosides ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles cognitifs peuvent survenir en raison de l'accumulation de gangliosides dans le cerveau."
}
},
{
"@type": "Question",
"name": "Les douleurs musculaires sont-elles un symptôme ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des douleurs musculaires peuvent être présentes en raison de l'atteinte des gangliosides."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les gangliosidoses ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention est limitée, mais le dépistage génétique peut aider à identifier les porteurs."
}
},
{
"@type": "Question",
"name": "Le conseil génétique est-il recommandé ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le conseil génétique est conseillé pour les familles à risque de gangliosidoses."
}
},
{
"@type": "Question",
"name": "Les vaccinations peuvent-elles aider ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les vaccinations ne préviennent pas les gangliosidoses, mais protègent contre d'autres maladies."
}
},
{
"@type": "Question",
"name": "L'alimentation peut-elle jouer un rôle préventif ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée peut soutenir la santé générale, mais ne prévient pas les gangliosidoses."
}
},
{
"@type": "Question",
"name": "Les tests de dépistage sont-ils utiles ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les tests de dépistage peuvent identifier les porteurs de mutations génétiques."
}
},
{
"@type": "Question",
"name": "Quels traitements existent pour les gangliosidoses ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent la thérapie enzymatique, la gestion des symptômes et le soutien psychologique."
}
},
{
"@type": "Question",
"name": "La thérapie génique est-elle une option ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La thérapie génique est en cours d'étude pour certaines gangliosidoses, mais n'est pas encore standard."
}
},
{
"@type": "Question",
"name": "Les médicaments peuvent-ils aider ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains médicaments peuvent soulager les symptômes, mais ne traitent pas la cause sous-jacente."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements expérimentaux disponibles ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des essais cliniques sont en cours pour de nouveaux traitements des gangliosidoses."
}
},
{
"@type": "Question",
"name": "Le soutien nutritionnel est-il important ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un soutien nutritionnel peut aider à améliorer la qualité de vie des patients."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des troubles neurologiques graves, des infections et des problèmes respiratoires."
}
},
{
"@type": "Question",
"name": "Les gangliosidoses peuvent-elles entraîner des handicaps ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines gangliosidoses peuvent entraîner des handicaps physiques ou mentaux permanents."
}
},
{
"@type": "Question",
"name": "Y a-t-il un risque accru de maladies associées ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les patients peuvent avoir un risque accru de maladies auto-immunes ou métaboliques."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "La plupart des complications des gangliosidoses ne sont pas réversibles et nécessitent une gestion."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion des complications nécessite une approche multidisciplinaire incluant médecins et thérapeutes."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque des gangliosidoses ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents familiaux, des mutations génétiques et des origines ethniques spécifiques."
}
},
{
"@type": "Question",
"name": "Les origines ethniques influencent-elles le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines populations, comme les Ashkénazes, ont un risque plus élevé de gangliosidoses."
}
},
{
"@type": "Question",
"name": "Les facteurs environnementaux jouent-ils un rôle ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, les facteurs environnementaux ne sont pas clairement établis comme des risques."
}
},
{
"@type": "Question",
"name": "Les antécédents médicaux familiaux sont-ils significatifs ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents médicaux de maladies métaboliques augmentent le risque de gangliosidoses."
}
},
{
"@type": "Question",
"name": "Les mutations génétiques sont-elles héréditaires ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les mutations génétiques responsables des gangliosidoses sont souvent héréditaires."
}
}
]
}
]
}
Intraocular pressure is currently the only known reliable, modifiable risk factor for the development and progression of glaucoma. Other risk factors for glaucoma include increasing age, myopia, decre...
Neuroanatomical variations across the visual field of human observers go along with corresponding variations of the perceived coarseness of visual stimuli. Here we show that horizontal gratings are pe...
Human visual performance changes dramatically both across (eccentricity) and around (polar angle) the visual field. Performance is better at the fovea, decreases with eccentricity, and is better along...
The earlier a person quits smoking the more likely is the optic nerve be spared from damage....
To investigate the effect of smoking cessation on visual field (VF) progression in glaucoma....
Primary open angle glaucoma patients with a minimum of 3 years follow-up and 5 VFs were included. Linear mixed models were used to investigate the effects of smoking on the rates of 24-2 VF mean devia...
Five hundred eleven eyes of 354 patients were included over the mean follow-up of 12.4 years. Mean baseline age (95% confidence interval) was 62.3 (61.2, 63.4) years. One hundred forty nine (42.1%) pa...
After ≥25 years of smoking cessation, the risk of VF progression in former heavy smokers becomes similar to never smokers. Long-term smoking cessation may be associated with lower VF progression in gl...
Previous studies have suggested behavioral patterns, such as visual attention and eye movements, relate to individual personality traits. However, these studies mainly focused on free visual tasks, an...
Despite, the potential clinical utility of 60-4 visual fields, they are not frequently used in clinical practice partly, due to the purported impact of facial contour on field defects. The purpose of ...
Subjects with no ocular pathology were included. Participants were subject to optical coherence tomography, 60-4 Swedish interactive thresholding algorithm visual field tests and photography. The pred...
30 healthy were enrolled. Three-dimensional facial reconstruction using a convolution neural network (CNN) was able to predict facial contour-dependent 60-4 visual field defects in 30 subjects without...
This pilot study reports the development of a CNN-enhanced platform capable of predicting 60-4 visual field defects in healthy controls based on facial contour. Further study with this platform may en...
To measure visual field (VF) rates of change after Ahmed Glaucoma Valve (AGV) implantation and to investigate risk factors for progression....
Retrospective, clinical cohort study....
Patients who underwent AGV implantation with at least 4 eligible postoperative VFs and 2 years of follow-up were included. Baseline, intraoperative, and postoperative data were collected. VF progressi...
A total of 173 eyes were included. The intraocular pressure (IOP) and number of glaucoma medications were significantly reduced from a median (interquartile range [IQR]) of 23.5 (12.1) mm Hg at baseli...
To our knowledge, this is the largest published series reporting long-term VF outcomes after glaucoma drainage device implantation. There is a continued, significant rate of VF decline after AGV surge...
To evaluate the relationship between interocular asymmetries of corneal hysteresis (CH) and visual field defects in Korean patients with glaucoma....
A total of 444 eyes from 222 participants with glaucoma in at least one eye were enrolled. CH was measured using an ocular response analyzer (Reichert Technologies Inc). Eyes of each participant were ...
Median (interquartile range) MD value was -3.71 dB (-6.87 to -1.30 dB) in the better eye and -10.20 dB (-16.32 to -5.62 dB) in the worse eye. When the correlation between the asymmetry of the MD value...
The interocular asymmetry of CH was significantly correlated with the interocular asymmetry of visual field defects in glaucoma....
To compare the accuracy of detecting moderate and rapid rates of glaucoma worsening over a 2-year period with different numbers of OCT scans and visual field (VF) tests in a large sample of glaucoma a...
Descriptive and simulation study....
The OCT sample comprised 12 150 eyes from 7392 adults with glaucoma or glaucoma suspect status followed up at the Wilmer Eye Institute from 2013 through 2021. The VF sample comprised 20 583 eyes from ...
Within-eye rates of change in retinal nerve fiber layer (RNFL) thickness and mean deviation (MD) were measured using linear regression. For each measured rate, simulated measurements of RNFL thickness...
The accuracy of diagnosing moderate and rapid rates of glaucoma worsening for different numbers of OCT scans and VF tests over a 2-year period....
Accuracy was less than 50% for both OCT and VF when diagnosing worsening after a 2-year period. OCT accuracy was 5 to 10 percentage points higher than VF accuracy at detecting moderate worsening and 1...
More frequent OCT scans and VF tests are needed to improve the accuracy of diagnosing glaucoma worsening. Accuracy greatly increases when relying on both OCT and VF to detect worsening....
The author(s) have no proprietary or commercial interest in any materials discussed in this article....
to compare visual field (VF) progression between the 2 arms of the Treatment of Advanced Glaucoma Study (TAGS)....
Post hoc analysis of VF data from a 2-arm, multicenter, randomized controlled clinical trial....
A total of 453 patients with newly diagnosed advanced open-angle glaucoma in at least 1 eye from 27 centers in the United Kingdom were randomized to either trabeculectomy (n = 227) or medication in th...
This study analyzed 211 eyes in the trabeculectomy first arm and 203 eyes in the medication first arm. The average RoP (estimate [95% credible intervals]) was -0.59 [-0.88, -0.31] dB/year in the medic...
There was no significant difference in the average RoP at 2 years....